BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BioCentury | Dec 7, 2018
Emerging Company Profile

ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer...
BioCentury | Oct 24, 2016
Emerging Company Profile

RORing against resistance

  Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. The Bruton’s tyrosine kinase...
BC Innovations | Nov 21, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Receptor tyrosine kinase-like orphan receptor 1 (ROR1); ROR2 In vitro and mouse studies suggest inhibiting ROR2 could help treat invasive...
BC Innovations | Mar 1, 2012
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) Receptor tyrosine kinase-like orphan receptor 2 (ROR2); wingless-type MMTV integration site family member 5A (WNT5A) Mouse studies suggest inhibiting WNT5A-ROR2 signaling...
Items per page:
1 - 6 of 6